Sweden's Apotea Q3 net revenue rises 12.5% on prescription products growth
Overview
Sweden online pharmacy's Q3 net revenue rose 12.5% yr/yr to SEK 1.99 bln
Adjusted EBIT for Q3 increased, with margin improving to 5.4%
Growth driven by prescription products and improved customer offering
Outlook
Company highlights prescription products as a key driver for future growth
Company expands same-day delivery to 3.7 mln people, aiming to enhance customer experience
Result Drivers
PRESCRIPTION PRODUCTS - Co said Q3 growth was driven by prescription products, with improved customer offering
NEW INITIATIVES - Co said it launched new initiatives to simplify shopping experience
SAME-DAY DELIVERY - Co said expanded same-day delivery to 3.7 mln people since September
Company press release:
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Net Revenue | SEK 1.99 bln | ||
Q3 Net Income | SEK 81.80 mln | ||
Q3 Cash Flow from Operating Activities | SEK 25.80 mln | ||
Q3 EBIT | SEK 107.40 mln | ||
Q3 EBIT Margin | 5.40% |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the drug retailers peer group is "buy"
Wall Street's median 12-month price target for Apotea AB (publ) is SEK92.50, about 3.2% below its November 4 closing price of SEK95.60
The stock recently traded at 28 times the next 12-month earnings vs. a P/E of 23 three months ago
Reuters Recommended Reads
Nov 4 - Sweden's Rugvista Q3 net revenue rises on high order volume
Nov 3 - Online fashion retailer Boozt Q3 revenue rises on wider assortment
Nov 3 - Zalando Q3 revenue slightly beats estimates on B2B expansion
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)